Compositions and methods for silencing ebola virus gene expression
The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.
1. A composition comprising an siRNA that silences Ebola virus VP24 expression consisting of the following sense and antisense strand sequences:
5′-UCC U CGACACGAA U GCAAAGU-3′
(SEQ ID NO. 10)
3′-CUA G GA G CUGUGCUUACG U UU-5′,
(SEQ ID NO. 17)
wherein the bolded and underlined nucleotides are 2′OMe nucleotides.
2. The composition of claim 1 , wherein the composition further comprises an siRNA that silences Ebola virus L-pol expression consisting of the following sense and antisense strand sequences:
5′-G U AC G AAGC UGU A U A U AAATT-3′
(SEQ ID NO. 2)
3′-TTCA U GCU U CGACAUA U AUUU-5′,
(SEQ ID NO. 6)
wherein the bolded and underlined nucleotides are 2′OMe nucleotides.
3. The composition of claim 1 , wherein the composition further comprises an siRNA that silences Ebola virus VP35 expression consisting of the following sense and antisense strand sequences:
5′- G CAAC U CAU U G G ACA U CA UU C-3′
(SEQ ID NO. 26)
3′-A U CG U U G AGUAACCU G UAG U A-5′,
(SEQ ID NO. 30)
wherein the bolded and underlined nucleotides are 2′OMe nucleotides.
4. The composition of claim 1 , wherein the composition further comprises:
(a) an siRNA that silences Ebola virus L-pol expression consisting of the following sense and antisense strand sequences:
5′-G U AC G AAGC UGU A U A U AAATT-3′
(SEQ ID NO. 2)
3′-TTCA U GCU U CGACAUA U AUUU-5′,
(SEQ ID NO. 6)
wherein the bolded and underlined nucleotides are 2′OMe nucleotides; and
(b) an siRNA that silences Ebola virus VP35 expression consisting of the following sense and antisense strand sequences:
5′- G CAAC U CAU U G G ACA U CA UU C-3′
(SEQ ID NO. 26)
3′-A U CG U U G AGUAACCU G UAG U A-5′,
(SEQ ID NO. 30)
wherein the bolded and underlined nucleotides are 2′OMe nucleotides.
5. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.
6. A nucleic acid-lipid particle comprising:
(a) a composition of claim 1 ;
(b) a cationic lipid; and
(c) a non-cationic lipid.
7. The nucleic acid-lipid particle of claim 6 , wherein the particle further comprises a conjugated lipid that inhibits aggregation of particles.
8. The nucleic acid-lipid particle of claim 6 , wherein the cationic lipid comprises 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-γ-dimlinolenyloxy-N,N-dimethylaminopropane (γ-DLenDMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)[1,3]-dioxolane (DLin-K-C2-DMA), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), or a mixture thereof.
9. The nucleic acid-lipid particle of claim 6 , wherein the non-cationic lipid is selected from the group consisting of a phospholipid, cholesterol, or a mixture of a phospholipid and cholesterol.
10. The nucleic acid-lipid particle of claim 9 , wherein the phospholipid comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof.
11. The nucleic acid-lipid particle of claim 9 , wherein the cholesterol is a cholesterol derivative.
12. The nucleic acid-lipid particle of claim 7 , wherein the conjugated lipid that inhibits aggregation of particles comprises a polyethyleneglycol (PEG)-lipid conjugate.
13. The nucleic acid-lipid particle of claim 12 , wherein the PEG-lipid conjugate is member selected from the group consisting of a PEG-diacylglycerol (PEG-DAG) conjugate, a PEG dialkyloxypropyl (PEG-DAA) conjugate, a PEG-phospholipid conjugate, a PEG-ceramide (PEG-Cer) conjugate, and a mixture thereof.
14. The nucleic acid-lipid particle of claim 13 , wherein the PEG-lipid conjugate is a PEG-DAA conjugate.
15. The nucleic acid-lipid particle of claim 14 , wherein the PEG-DAA conjugate is selected from the group consisting of a PEG-didecyloxypropyl (C 10 ) conjugate, a PEG-dilauryloxypropyl (C 12 ) conjugate, a PEG-dimyristyloxypropyl (C 14 ) conjugate, a PEG-dipalmityloxypropyl (C 16 ) conjugate, a PEG-distearyloxypropyl (C 18 ) conjugate, and a mixture thereof.
16. The nucleic acid-lipid particle of claim 6 , wherein the composition is fully encapsulated in the nucleic acid-lipid particle.
17. A pharmaceutical composition comprising a nucleic acid-lipid particle of claim 6 and a pharmaceutically acceptable carrier.
18. A method for introducing an siRNA that silences Ebola virus gene expression into a cell, the method comprising:
contacting the cell with a nucleic acid-lipid particle of claim 6 .
19. A method for silencing Ebola virus gene expression in a mammal in need thereof, the method comprising:
administering to the mammal a nucleic acid-lipid particle of claim 6 .
20. A method for the in vivo delivery of an siRNA that silences Ebola virus gene expression, the method comprising:
administering to a mammal a nucleic acid-lipid particle of claim 6 .
21. A method for treating and/or ameliorating one or more symptoms associated with an Ebola virus infection in a mammal in need thereof, the method comprising:
administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle of claim 6 .
22. A method for inactivating and/or inhibiting the replication of Ebola virus in a mammal in need thereof, the method comprising:
administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle of claim 6 .
23. A method for preventing and/or treating hemorrhagic fever in a mammal in need thereof, the method comprising:
administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle of claim 6 .